New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
10:01 EDTTRLA, DLA, MLNX, PFE, VCLK, OPTR, FIO, SYRG, RBCN, FLY, ABBV, VRTX, GOOGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Delta Apparel (DLA) initiated with a Buy at Roth Capital... Fly Leasing (FLY) initiated with a Buy at Deutsche Bank... Google (GOOG) initiated with a Neutral at Sterne Agee... Optimer (OPTR) initiated with an Outperform at RW Baird... Trulia (TRLA) initiated with a Neutral at Goldman... ValueClick (VCLK) initiated with a Buy at Goldman... Vertex (VRTX) initiated with an Outperform at RW Baird... Rubicon (RBCN) coverage resumed with an Underweight at Piper Jaffray... Synergy Resources (SYRG) initiated with a Buy at Canaccord... Pfizer (PFE) reinstated with a Neutral at Credit Suisse... AbbVie (ABBV) initiated with a Neutral at Credit Suisse... Fusion-io (FIO) initiated with a Neutral at Janney Capital... Mellanox (MLNX) initiated with a Buy at Janney Capital.
News For GOOG;DLA;FLY;OPTR;TRLA;RBCN;VCLK;VRTX;SYRG;PFE;ABBV;FIO;MLNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 8, 2015
05:30 EDTABBVEnanta announces data on regimens containing protease inhibitors paritaprevir
Subscribe for More Information
April 7, 2015
16:27 EDTGOOGFTC to review complaints against YouTube Kids app, Washington Post says
Subscribe for More Information
13:59 EDTGOOGGoogle says Google Moderator to shut down on July 31
Google says its Google Moderator will shut down on July 31. The company says, "Unfortunately, Google Moderator has not had the usage we had hoped, so weíve made the difficult decision to close down the product. We want to ensure users have enough time to export their Moderator series data using our Takeout tool. Please take a look at the timeline below for more information. March 30 is the first day that you can download your Google Moderator data from Takeout. Your data from past Moderator series will be available in Takeout for at least two years. June 30 will be the last day you can create a new series, ask a question, or vote on a question. For the month of July, Google Moderator will be 'read-only. July 31 is Moderatorís last day. The site will no longer be available in any form, but you will be able to access data from past Moderator series through our Takeout tool for at least two years." Reference Link
08:09 EDTPFEPfizer, Merck KGaA finalize agreement to co-promote XALKORI
Merck KGaA (MKGAY) and Pfizer (PFE) announced the finalization of the co-promotion agreement allowing the companies to co-promote Pfizerís anaplastic lymphoma kinase inhibitor XALKORI. Under the agreement, XALKORI will be co-promoted in two waves, the first of which will begin in the second and third quarters of 2015 in the United States, Canada, Japan and five European Union countries: France, Germany, Italy, Spain and the United Kingdom. In the U.S. and Canada, XALKORI will be co-promoted by EMD Serono, the U.S. and Canadian biopharmaceutical businesses of Merck KGaA. The second wave will begin in 2016 and includes China and Turkey. n 2015, Merck KGaA will receive a reimbursement associated with its promotion of XALKORI, followed by an 80% for Pfizer, 20% for Merck KGaA profit sharing on the product starting in 2016. The co-promotion term will last through December 31, 2020 for the U.S., Canada, Japan, France, Germany, Italy, Spain and the U.K. and from January 1, 2016 through December 31, 2021 in China and Turkey. Pfizer will report the sales of XALKORI in countries where it is co-promoted with Merck KGaA.
07:31 EDTABBVBiogen to present data on neurological disease therapies at AAN meeting
Subscribe for More Information
07:14 EDTPFEEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
07:03 EDTGOOGCyrusOne announces direct connectivity to Google Cloud Platform
Subscribe for More Information
07:02 EDTPFEGlycoMimetics updates on Pfizer's plans to initiate Phase 3 Rivipansel trial
Subscribe for More Information
06:46 EDTGOOGApple Pay, Google Wallet could see competition from CurrentC, Macworld says
Subscribe for More Information
06:25 EDTGOOGGroups urge authorities to probe YouTube app, Reuters says
Advocacy groups say they will urge federal regulators to probe a video app for Google's YouTube, according to Reuters. Aimed at children, the app deceptively blends video programming and ads, the news service quoted the groups as saying. Reference Link
06:21 EDTGOOGGoogle Ventures leading $12M investment in CoreOS, Business Insider reports
Subscribe for More Information
06:00 EDTGOOGTurkey restores access to YouTube, Twitter, Facebook, FT reports
Subscribe for More Information
April 6, 2015
19:42 EDTGOOGSurvey of iPhone, iPad users indicates preference for Google search, BI says
48% of Apple (AAPL) iPhone and iPad users report that if Yahoo (YHOO) were to acquire default search engine rights for Apple's Safari browser, they would manually switch the default search back to Google (GOOG), reports Business Insider, citing a survey of roughly 500 Apple users by Goldman Sachs tech analysts. 4% of the surveyed users stated they would intentionally keep Yahoo as the default. Reference Link
10:37 EDTPFETargacept says Pfizer terminates research & license agreement with Catalyst
In a regulatory filing from earlier, Targacept (TRGT) said: "As previously reported, on March 5, Targacept, Talos Merger Sub, a Delaware corporation and a wholly owned subsidiary of Targacept and Catalyst Biosciences, entered into an Agreement and Plan of Merger, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Catalyst, with Catalyst becoming a wholly owned subsidiary of Targacept and the surviving corporation of the merger. On April 1, Catalyst notified Targacept that Pfizer (PFE) would be exercising its right to terminate in its entirety the June 29, 2009, research and license agreement between Catalyst and Wyeth, which governs the development and commercialization of Catalystís leading human Factor VIIa product candidate for the treatment of hemophilia and surgical bleeding indications. On April 2, Pfizer provided Catalyst with its formal written notice of termination of the research and license agreement. Upon the June 1, effective date of the termination, the license and certain rights under the research and license agreement will terminate and revert to Catalyst. Catalyst has informed Targacept that Pfizer is committed to an orderly transfer of data, regulatory documentation and related technology under the agreement to Catalyst to enable Catalyst to continue the clinical development of this product candidate. Targacept is currently reviewing the implications of this event on the proposed Merger. In morning trading shares of Targacept are down almost 12% to $2.51.
09:56 EDTGOOGGoogle in talks with Hutchison for cheaper overseas calls, Telegraph reports
Subscribe for More Information
09:36 EDTGOOGActive equity options trading on open
Subscribe for More Information
06:32 EDTGOOGGoogle Ventures-backed Buttercoin to shut down
Subscribe for More Information
05:54 EDTGOOGYouTube planning advertising campaign aimed at Canada, Globe and Mail says
Subscribe for More Information
April 5, 2015
16:56 EDTGOOGEU considers major probe into Internet platforms, WSJ says
Subscribe for More Information
14:32 EDTGOOGAntitrust suit against Google over Android app limits dropped, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use